Brief: Cognition Therapeutics Announces Positive Topline Results For CT1812 Phase 2 Sequel Study
28/06/2023 12:38
June 28 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS
FOR
CT1812 PHASE 2 SEQUEL STUDY FOR MILD-TO-MODERATE ALZHEIMER’S
DISEASE
* COGNITION THERAPEUTICS - PHASE 2 DOUBLE-BLIND,
SINGLE-CROSSOVER
SEQUEL STUDY OF CT1812 MET ITS PRIMARY ENDPOINTS FOR SAFETY AND
TOLERABILITY
* COGNITION THERAPEUTICS - STUDY SHOWED POSITIVE EFFECTS FOR
CT1812-TREATED PARTICIPANTS AS MEASURED VIA QUANTITATIVE
ELECTROENCEPHALOGRAM
Source text for Eikon: ID:nGNX7nWFw8
Further company coverage: CGTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB